ArticleInternational journal of surgery case reports2024
Conversion hepatectomy after chemotherapy including nivolumab for multiple liver metastases of hepatoid adenocarcinoma of the stomach: A case report and literature review.
Article in International journal of surgery case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A multicenter retrospective study of PD-1 blockade plus chemotherapy as first-line therapy in advanced hepatoid adenocarcinoma of the stomach.The oncologist · 2025Article
- Case Report: Pathologic complete response to PRaG therapy in an elderly patient with refractory metastatic gastric cancer.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCurrently, there is no evidence of the effectiveness of surgical intervention for Stage IV gastric cancer (GC); however, there are scattered reports of hepatectomy for liver metastasis of GC after chemotherapy including nivolumab. PRESENTATION OF CASE: We report a case of a 79-year-old man with a history of laparoscopic distal gastrectomy with D2 lymph node dissection for GC, pathologically diagnosed as hepatoid adenocarcinoma of the stomach (HAS), with a combined positive score (CPS) for programmed death (PD)-ligand 1 was >5. Six months after gastrectomy, magnetic resonance imaging (MRI) showed multiple masses in both lobes of the liver, and the patient was treated with a regimen consisting of nivolumab and capecitabine with oxaliplatin (CapeOX). After 11 courses of nivolumab and CapeOX therapy, MRI revealed reduced tumor sizes in both lobes of the liver. The patient underwent left lateral sectionectomy and partial resection of the liver. No new recurrences were observed, and the patient has survived for 15 months after hepatectomy. DISCUSSION: The recent emergence of PD-1 inhibitors has improved the prognosis of unresectable advanced or recurrent GC. Hepatectomy for liver metastasis of GC can be effective if the conditions are met. In this case, both the resected gastric tumor and metastasis in the left lateral hepatic segment had a CPS > 5, suggesting that nivolumab with CapeOX therapy could control the disease status from unresectable to resectable liver metastasis.
conclusionUsing multidisciplinary treatment, R0 surgery was successfully performed in a patient with multiple unresectable liver metastases of HAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.